NRx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NRx Pharmaceuticals generated cash of -$21,657,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,201,000 last year. Net change in cash is therefore -$15,459,000.
Cash Flow
| 2017 | -135.80K | -69M | 69.58M |
|---|---|---|---|
| 2018 | -473.18K | -647.60K | 682.5K |
| 2019 | -792.73K | 40.24M | -39.46M |
| 2020 | -2.26M | -2K | 3.24M |
| 2021 | -37.70M | -7K | 63.45M |
| 2022 | -39.75M | -10K | 32.21M |
| 2023 | -21.65M | -3K | 6.20M |
NRXPW Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 20.05M | 27.60M | 1.85M | 877K | 11.07K | 449.37K | 0 |
Operating activities | |||||||
Net income | -30.15M | -39.75M | -93.06M | -51.77M | 408.42K | 66.10K | -105.03K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 5K | 4K | 2K | 2K | 0 | 0 | 0 |
Stock-based compensation expense | 387K | 3.62M | 7.78M | 730K | 933 | 0 | 0 |
| Deferred income tax benefit | 387K | 3.62M | 7.78M | 730K | 933 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 831K | -831K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.65M | -1.61M | -19K | 1.18M | 71.34K | 465.42K | 85.67K |
Cash generated by operating activities | -21.65M | -39.75M | -37.70M | -2.26M | -792.73K | -473.18K | -135.80K |
Investing activities | |||||||
Purchases Of Investments | 0 | -10K | -7K | 0 | -993.09K | -690K | -69M |
Investments In Property Plant And Equipment | -3K | -10K | -7K | -2K | -3 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3K | -10K | -7K | -2K | 40.24M | -647.60K | -69M |
Financing activities | |||||||
Common Stock Issued | 8.12M | 22.70M | 36.98M | 2.57M | 0 | -7.5K | 69.58M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -40.72M | 0 | 70.02M |
Repayments of term debt | -3.09M | 9.50M | -1.27M | -620K | 0 | -690K | 0 |
Cash used in financing activities | 6.20M | 32.21M | 63.45M | 3.24M | -39.46M | 682.5K | 69.58M |
Net Change In Cash | -15.45M | -7.55M | 25.74M | 982K | -11.07K | -438.29K | 449.37K |
Cash at end of period | 4.59M | 20.05M | 27.60M | 1.85M | 6 | 11.07K | 449.37K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |